Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Discount Card “Minimum Formulary” Includes 209 Drug Classes

Executive Summary

The Medicare-endorsed discount card program will define 209 drug categories in which card sponsors must offer a discounted drug

You may also be interested in...



Medicare Rx “Debit Card” Will Fund $5 Bil. In Drug Purchases, CMS Estimates

The Medicare discount card program will provide $2.4 bil. in federal funds to support drug purchases by low-income seniors during 2004, CMS estimates

Medicare Rx “Debit Card” Will Fund $5 Bil. In Drug Purchases, CMS Estimates

The Medicare discount card program will provide $2.4 bil. in federal funds to support drug purchases by low-income seniors during 2004, CMS estimates

USP To Help Set Formulary Rules Under Medicare Rx Bill

The U.S. Pharmacopeia would play a central role in setting the ground rules for formularies under the Medicare prescription drug bill

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel